Results 261 to 270 of about 451,544 (302)
Some of the next articles are maybe not open access.
[Growth hormone deficiency. Treatment with growth hormone and body composition].
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1998Increased fat mass, decreased lean mass, muscular mass and bone mineral density are characteristic of the body composition in GH deficiency, GH treatment reverses these abnormalities. Body composition was determined in 20 young adults with GHD diagnosed in childhood, whose GH treatment was stopped 1 year earlier.
ANTONIAZZI, Franco +6 more
openaire +2 more sources
Growth hormone treatment in non-growth hormone-deficient short children
Journal of Endocrinological Investigation, 2005The unlimited availability of GH obtained by recombinant DNA technology has allowed optimization of treatment in GH-deficient (GHD) children. At the same time it has prompted a number of studies in conditions not characterized by GHD such as Turner syndrome, intrauterine growth retardation, chronic renal failure and other chromosomal and genetic ...
S, Loche +3 more
openaire +2 more sources
Antibodies to Porcine Growth Hormone Induced by Treatment with Human Growth Hormone
The Journal of Clinical Endocrinology & Metabolism, 1971ABSTRACT Antibodies to human growth hormone (HGH) were detected in low titer in 3 of 15 patients on HGH therapy for 2–7 yr, and in none of 12 patients on HGH therapy for 3–11 months. The binding of [125I] HGH was used as a criterion. Using [125I] porcine growth hormone (PGH), however, antibodies were detected in titers of 1:128 to 1:320,000 in 11 of ...
G, Murthy, E E, McGarry
openaire +2 more sources
Growth and Growth Hormone Treatment in Noonan Syndrome.
Pediatric endocrinology reviews : PER, 2019Short stature is a common characteristic of Noonan Syndrome (NS), a genetic condition caused by mutations affecting the RAS / mitogen-activated protein kinase (MAPK) cascade. Growth hormone (GH) has been used to normalize childhood growth and increase adult height in NS.
openaire +2 more sources
Long-term growth hormone treatment in growth hormone deficient adults
Acta Endocrinologica, 1991Abstract. Growth hormone treatment in GH-deficient adults has proved beneficial in recent short-term trials, but long-term results have not yet been reported. Thirteen GH-deficient adults (4 females, 9 males; mean (sem) age 26.4 (1.7) years), who had completed 4 months of GH therapy in a double-blind placebo-controlled cross-over study were followed ...
J O, Jørgensen +7 more
openaire +2 more sources
Hormone Research, 2008
Non-compliance has been reported as a major issue in growth hormone (GH) therapy. We explored the use of urinary GH (uGH) measurements to monitor the GH treatment of 18 children (aged 5-16 years) diagnosed as GH deficient on the basis of history, phenotype, auxology and peak GH concentration during 2 provocation tests of < 15 mU/l.
Skinner, A. M. +3 more
openaire +2 more sources
Non-compliance has been reported as a major issue in growth hormone (GH) therapy. We explored the use of urinary GH (uGH) measurements to monitor the GH treatment of 18 children (aged 5-16 years) diagnosed as GH deficient on the basis of history, phenotype, auxology and peak GH concentration during 2 provocation tests of < 15 mU/l.
Skinner, A. M. +3 more
openaire +2 more sources
2013
Approximately 8–10 % of children born small for gestational age (SGA) do not show catch-up growth by the age of 2 years and older [1, 2], with approximately 10 % of all children born SGA still below the third percentile at the age of 8 years [3]. These children later have a reduced adult height [4].
openaire +1 more source
Approximately 8–10 % of children born small for gestational age (SGA) do not show catch-up growth by the age of 2 years and older [1, 2], with approximately 10 % of all children born SGA still below the third percentile at the age of 8 years [3]. These children later have a reduced adult height [4].
openaire +1 more source
Growth Hormone Treatment in Adults with Growth Hormone Deficiency
1993As a clinical entity, growth hormone (GH) deficiency in adulthood has previously received little attention. This has been due in part to a traditional view that GH is only of physiological importance during childhood and adolescence, when its effects are most visible and dramatic, despite the fact that GH secretion normally continues throughout adult ...
A. J. Weissberger +5 more
openaire +1 more source
Growth Hormone Treatment for Short Stature
New England Journal of Medicine, 1983Fifteen short but otherwise normal children, 4.3 to 15.5 years old, with heights greater than 3 S.D. below the mean value for age, growth rates less than or equal to 5.0 cm per year, and normal serum levels of immunoreactive growth hormone in response to provocative stimuli (peak greater than or equal to 10 ng per milliliter) were treated with ...
G, Van Vliet +3 more
openaire +2 more sources
Growth hormone-releasing hormone: a new treatment for growth hormone deficiency
1989The identification and synthesis of growth hormone-releasing hormone (GHRH) coincided with the realisation that Jacob-Creutzfeldt disease could be transmitted by extracted cadaveric GH. Fortunately, the acceleration in supplies of biosynthetic GH enabled treatment regimens to be continued and even extended, and the field of growth and its therapy has ...
R. J. M. Ross +3 more
openaire +1 more source